Day One Biopharmaceuticals (NASDAQ:DAWN) CEO Sells $141,615.54 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 15,894 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $8.91, for a total value of $141,615.54. Following the transaction, the chief executive officer owned 177,165 shares of the company’s stock, valued at approximately $1,578,540.15. This represents a 8.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Day One Biopharmaceuticals Price Performance

DAWN stock traded down $0.27 during trading on Tuesday, reaching $8.57. The company had a trading volume of 1,531,756 shares, compared to its average volume of 1,496,830. The company has a market cap of $879.97 million, a P/E ratio of -5.64 and a beta of -1.25. The business has a 50 day moving average of $7.63 and a 200 day moving average of $7.05. Day One Biopharmaceuticals, Inc. has a 52 week low of $5.64 and a 52 week high of $14.46.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.09. The company had revenue of $39.80 million for the quarter, compared to the consensus estimate of $38.20 million. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. Day One Biopharmaceuticals’s revenue for the quarter was down 57.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.38 EPS. Research analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

DAWN has been the topic of several analyst reports. Piper Sandler lifted their price target on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Needham & Company LLC cut their target price on shares of Day One Biopharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. HC Wainwright decreased their price target on shares of Day One Biopharmaceuticals from $36.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. Zacks Research upgraded shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research report on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Day One Biopharmaceuticals has an average rating of “Moderate Buy” and an average target price of $24.43.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Day One Biopharmaceuticals during the first quarter worth about $384,000. Ieq Capital LLC purchased a new position in shares of Day One Biopharmaceuticals during the 1st quarter worth $294,000. Allianz Asset Management GmbH purchased a new stake in shares of Day One Biopharmaceuticals in the first quarter valued at about $198,000. Parkman Healthcare Partners LLC grew its stake in shares of Day One Biopharmaceuticals by 4.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 1,043,162 shares of the company’s stock valued at $8,272,000 after buying an additional 42,688 shares during the period. Finally, Trexquant Investment LP grew its stake in shares of Day One Biopharmaceuticals by 132.8% in the 1st quarter. Trexquant Investment LP now owns 204,782 shares of the company’s stock valued at $1,624,000 after buying an additional 116,810 shares during the period. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.